Total Funding
92
89
Total FundingVenture - Series Unknown raised
Growth Score
8 pts
Heat Score
19 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
6193
Prelude delivers actionable tools to manage early stage breast cancer with the DCIS test that enables personalized treatment.
- Edwin Hendrick: Chief Commercial OfficerPast Role: Biocept, Chief Commercial Officer
- Andy Wade: CFO
About the Company
PreludeDx was founded with the goal of providing better decision-making tools to breast cancer patients and physicians. Founded in 2009 with technology licensed from the University of California San Francisco, PreludeDx has focused on developing breast cancer tools that will impact a patient’s treatment decision. Their mission is to provide tools
that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system.
